South Miami Hospital Harry Kapp Symposium, 26th Annual - Cutting Edge Trends in Lung Health

Miami, FL US
September 29, 2018

COPD is a common chronic respiratory ailment and a major driver of health care expenditure. Creating care plans for patients with COPD requires concurrent attention to nuances in disease presentation and the application of multidisciplinary resources to optimize health care utilization. This symposium will address the need for clinical programs to assess and manage patients’ treatable traits, diagnosis, treatment and long-term management of interstitial pulmonary fibrosis and nontuberculous mycobacterial infections, as well as the effects of e-cigarettes and vaping on human immune response.

Target Audience

Pulmonologists, Critical Care Medicine Physicians, Pathologists, Family Practice Physicians, General Internists, Hospitalists, Nurses, Respiratory Therapists, Occupational Therapists, Pharmacists and other interested healthcare providers.

 

Learning Objectives

  • Review our current approach to identifying phenotypes and endotypes versus treatable traits in COPD.
  • Discuss how such characterization allows us to personalize treatment and consider novel biologic agents for treatment of COPD in the future.
  • Analyze the expanding use of e-cigarettes among adolescents.
  • Discuss potential toxicities associated with vaping, and the effects of e-cigarettes and vaping on human immune response.
  • Implement evidence-based recommendations for the diagnosis and management of interstitial pulmonary fibrosis (IPF).
  • Effectively identify cases of IPF, review diagnosis and initiate appropriate treatment.
  • Discuss some of the latest research on acute respiratory distress syndrome (ARDS)
  • Implement evidence-based strategies in the treatment of patients with ARDS to improve patient outcomes. 
  • Implement evidence-based follow-up care for patients presenting with IPF, and provide ongoing monitoring to improve patient outcomes.
  • Identify traditional risk factors and presentation of pulmonary nontuberculous mycobacterial (NTM) infection.
  • Construct an appropriate diagnostic and treatment strategy for patients with suspected NTM.
Additional information
Course summary
Available credit: 
  • 5.50 AMA PRA Category 1 Credit™
  • 5.50 Florida Board of Nursing
  • 5.50 Nurse Practitioners
  • 5.50 Florida Board of Occupational Therapy
  • 5.50 Florida Board of Pharmacy
  • 5.50 Florida Board of Respiratory Therapy
  • 5.50 General certificate of attendance
Course opens: 
04/26/2018
Course expires: 
10/26/2018
Event starts: 
09/29/2018 - 8:00am
Event ends: 
09/29/2018 - 3:00pm
Rating: 
0

8:00 a.m.     Registration
8:15 a.m.     Welcome and Introductions
8:30 a.m.     Vaping: Perspectives from an Inhalation Toxicologist Who Is Also A Mother Of Teenagers
                    Ilona Jaspers, Ph.D.
9:30 a.m.     New Treatment Options for COPD: Phenotypes, Endotypes or Treatable Traits?
                    Ronald C. Balkissoon, M.D.
10:30 a.m.   Break
10:45 a.m.   Interstitial Pulmonary Fibrosis
                    Mark Rumbak, M.D.
11:45 a.m.   Lunch
12:30 p.m.   State of the Art: Treating Nontuberculous Mycobacterial Infections
                    Jorge Murillo, M.D.
1:30 p.m.     Acute Respiratory Distress Syndrome
                    Juan Francisco Rodriguez-Moran, M.D.
2:30 p.m.     Q&A
3:00 p.m.     Adjourn

South Miami Hospital
6200 SW 73 St
Victor E. Clarke Auditorium
Miami, FL 33143
United States

Juan Francisco Rodriguez-Moran, M.D.
Pulmonologist
Baptist, Doctors, Homestead, South Miami and West Kendall Baptist Hospital

Juan Francisco Rodriguez-Moran, M.D. indicated that neither he nor his spouse/partner have relevant financial relationships with commercial interest companies, and he will not include off-label or unapproved product usage in his presentation or discussion.

Ronald C. Balkissoon, M.D.
Associate Professor, Department of Medicine, Pulmonary
National Jewish Medical and Research Center
Associate Professor, Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine and Department of Preventive Medicine and Biometrics
University of Colorado School of Medicine
Denver, Colorado

Ronald Balkissoon, M.D. has indicated that he is a Consultant for Astra Zeneca, Genentech and Glaxo Smith Klein.  He is also a member of the speakers’ bureau for Astra Zeneca, Sunovion, and Genentech. Dr. Balkissoon has indicated that he will not include off-label or unapproved product usage in her presentation or discussion.

Ilona Jaspers, Ph.D.
Professor, Departments of Pediatrics, Microbiology & Immunology, and Environmental Science & Engineering
Director, Curriculum in Toxicology
Deputy Director, Center for Environmental Medicine, Asthma & Lung Biology
University of North Carolina at Chapel Hill School of Medicine
Chapel Hill, North Carolina

Ilona Jaspers, Ph.D. indicated that neither she nor her spouse/partner have relevant financial relationships with commercial interest companies, and she will not include off-label or unapproved product usage in her presentation or discussion.

Mark Rumbak, M.D.
Professor, College of Medicine Internal Medicine
University of South Florida,
Tampa, Florida

Mark Rumback, M.D. indicated that neither he nor his spouse/partner has relevant financial relationships with commercial interest companies, and he will not include off-label or unapproved product usage in his presentation(s) or discussion(s).

Jorge R. Murillo, M.D.
Infectious Disease Physician
South Miami Hospital
Miami, Florida

Jorge Murillo, M.D. indicated that neither he nor his spouse/partner has relevant financial relationships with commercial interest companies, and he will not include off-label or unapproved product usage in his presentation(s) or discussion(s).

*Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose.

Disclosure Policy and Disclaimer

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.

Baptist Health South Florida designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been approved for 5.5 credit hours by the Florida Boards of Medicine, Osteopathic Medicine, and the Florida Council of Physician Assistants. CE Broker #20-632909.

This activity has also been approved for 5.5 credits for Nurses, Nurse Practitioners, Occupational Therapists, Respiratory Therapists and Pharmacists. Baptist Health South Florida CE Broker Provider #50-182.

The American Academy of Nurse Practitioners Certification Board (AANPCB) accepts CEs accredited by the ACCME.  Individuals are responsible for checking with the AANPCB for further guidelines.

.

Available Credit

  • 5.50 AMA PRA Category 1 Credit™
  • 5.50 Florida Board of Nursing
  • 5.50 Nurse Practitioners
  • 5.50 Florida Board of Occupational Therapy
  • 5.50 Florida Board of Pharmacy
  • 5.50 Florida Board of Respiratory Therapy
  • 5.50 General certificate of attendance

Accreditation Period

Course opens: 
04/26/2018
Course expires: 
10/26/2018
Please login or register to take this course.

Required Hardware/software

Technical Support: If you are experiencing technical difficulties or have received an error message, please send an email to CME@BaptistHealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.

Technical Support